Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).

Ozguroglu, Mustafa

Beuzeboc, Philippe

Massard, Christophe

Rouge, Thibault De La Motte

Delanoy, Nicolas

Elaidi, Reza-Thierry

Oudard, Stephane

Angelergues, Antoine

Maillet, Denis

Flechon, Aude

Mercier, Florence

Guillot, Aline

Le Moulec, Sylvestre

Gravis, Gwenaelle